Is P-21 a cheaper substitute for a cerebrolysin course?

No. It is cheaper, at an ESTIMATED $29 to $48 a month against an ESTIMATED $500 to $900, and it is not a substitute. Cerebrolysin has thousands of human trial participants across stroke, brain injury and dementia. P-21 has zero registered human trials, so the lower price buys an untested compound rather than the same result for less.

Which one scores higher on BioHarmony?

Cerebrolysin, 6.3 and worth trying, against P-21 at 5.0 and neutral. A 5.0 is the middle of the scale and means the evidence does not support a recommendation in either direction. The gap is almost entirely evidence quality: cerebrolysin scores 3.6 on evidence and P-21 scores 1.5.

Does P-21 actually work?

In rodents, repeatedly and across models. It is brain-penetrant, orally active, lowers tau and lifts hippocampal neurogenesis, per Kazim 2014 and Khatoon 2015. In humans, nobody knows, because no trial has been run. The single independent in-vivo test failed to raise BDNF or improve neuroanatomy in knockout mice, per Mottolese 2024, which is the one result not authored by the inventor.

Can I take P-21 orally instead of injecting it?

P021 was orally active in rodents, which is a genuine pharmacologic strength most peptides lack. There is no human oral dosing standard, so any oral protocol you find is extrapolation. The same caution applies to the intranasal route: nose-to-brain delivery in people has never been measured, and the higher acute doses vendors push are folklore rather than protocol.

Can I stack cerebrolysin and P-21?

There is no reason to and no data supporting it. Both converge on BDNF-like neurotrophic signaling, so the mechanisms are redundant rather than complementary. Running two growth-factor mimetics together multiplies the theoretical proliferation concern that already puts active cancer on both contraindication lists, with nothing measured to offset it.

Will either one make a healthy brain sharper?

No trial says so. Cerebrolysin's contraindication list explicitly names healthy adults seeking cognitive enhancement, because no study shows benefit in a well brain, and its human record sits entirely in disease recovery. P-21 has no human data of any kind. The cognition subratings, 4.2 and 2.5, both describe recovery or rodent contexts.

Who should avoid both?

Anyone with active or suspected cancer, anyone pregnant or breastfeeding, and anyone with epilepsy or a seizure history. Cerebrolysin adds known allergy to porcine-derived protein, severe renal impairment and unsupervised IV self-administration without sterile technique. P-21 adds anyone who wants a cognitive intervention with human evidence behind it, since it has none.

Head-to-Head Comparison

Cerebrolysin vs P-21: Which Is Better for Brain Repair?

Should I run a cerebrolysin course or take P-21 instead?

Reviewed 09/08/2026

Cerebrolysin scores 6.3 and P-21 scores 5.0, and the gap is entirely about human data. Cerebrolysin has thousands of trial participants, contested by two independent Cochrane reviews. P-21 has zero human trials and one failed independent replication of its core mechanism. Cheap and untested is not the cheaper option.

Cerebrolysin 6.3 and worth trying. P-21 5.0 and neutral, which means the data does not support a recommendation in either direction.
P-21 is marketed as the cheap oral or intranasal stand-in for an injectable neuro-repair course. There is no human study behind that pitch. None.
Cerebrolysin's human record is real and contested at once: positive maker-funded trials, two null-to-negative Cochrane reviews, one flagging more non-fatal serious adverse events.
P-21's mouse file is clean and broad, which is exactly why the missing human file deserves to be loud. The one independent in-vivo test failed to reproduce its BDNF effect.
Cost inverts the picture. An ESTIMATED $500 to $900 a month of imported ampoules plus clinic fees against an ESTIMATED $29 to $48 a month of research-chemical vials.
Neither is proven for a healthy brain. Cerebrolysin's own contraindication list names healthy adults seeking cognitive enhancement, because no trial shows benefit in a well brain.

At a Glance

Option A

Cerebrolysin

6.3 / 10 Worth trying

Upside

Efficacy 3.5
Breadth 3.8
Evidence 3.6
Speed 3.2
Durability 2.8
Bioindividuality 3.2

Downside

Safety Risk 2.0
Side Effects 2.3
Cost 3.0
Effort 4.0
Opportunity Cost 3.0
Dependency 1.8
Reversibility 1.6

Best at:

Neuroprotection 4.5
TBI 4.3
Cognition Focus 4.2
Memory 4.0

Porcine brain-derived peptide mixture given by IV or IM infusion. BioHarmony 6.3, worth trying.

Read full BioHarmony report →

Option B

P21 (P021)

5.0 / 10 🤷 Neutral

Upside

Efficacy 3.0
Breadth 2.8
Evidence 1.5
Speed 2.5
Durability 2.5
Bioindividuality 2.5

Downside

Safety Risk 2.0
Side Effects 1.9
Cost 3.0
Effort 2.8
Opportunity Cost 3.2
Dependency 1.6
Reversibility 2.0

Best at:

Cognition Focus 2.5
Memory 2.5
Neuroprotection 2.5
Neuroplasticity 2.5

CNTF-derived peptidomimetic sold as a research chemical, injected or sprayed. BioHarmony 5.0, neutral.

Read full BioHarmony report →

Head-to-Head Verdict

Use Case	Winner	Rationale
TBI	Cerebrolysin	Cerebrolysin 4.3 against 2.0, the widest gap here, and it is a gap between species. CAPTAIN II randomized 142 patients at Glasgow Coma Scale 7 to 12 and found a significant benefit at day 90, per Muresanu 2020, confirmed at day 30 and day 90 by Vester 2021. P-21's whole brain-injury case is one mouse model, per Chohan 2015. Both cerebrolysin trials are maker-funded.
Neuroprotection	Cerebrolysin	Cerebrolysin 4.5 against 2.5, and neither side is settled. Cerebrolysin is the only one with human data, though the independent Cochrane stroke review found no benefit on death and more non-fatal serious adverse events, per Ziganshina 2023. P-21 lowered tau in Alzheimer's-model mice, per Kazim 2014, and then the one independent in-vivo test failed, per Mottolese 2024.
Cognition Focus	Cerebrolysin	Cerebrolysin 4.2 against 2.5, and the caveat outweighs the number. Pooled Alzheimer's trials showed a cognitive effect of about 0.40 at four weeks that faded by six months, per Gauthier 2015, authored by maker affiliates. That is recovery-context cognition, not a study aid. P-21 rescued learning in rodents, per Li 2010, and nothing in a person.
Memory	Cerebrolysin	Cerebrolysin 4.0 against 2.5, on the same dementia base. Alzheimer's cognitive measures improved early then faded by six months, per Gauthier 2015, and the vascular dementia effect was rated very low quality with every study industry-funded, per Cui 2019. P-21 improved rodent memory, per Li 2010 and Kazim 2014. No healthy-population trial exists either side.
Geriatric	Cerebrolysin	Cerebrolysin 2.5 against 2.0, and both are low for a reason. Older adults are the population cerebrolysin was actually studied in, but the cognitive effect faded by six months, per Gauthier 2015, and the independent vascular dementia evidence was rated very low quality, per Cui 2019. P-21 reversed neurogenesis deficits in aged rats, per Bolognin 2014, and stops there.
Neuroplasticity	Tie	The one row P-21 edges on subrating, 2.5 against 2.2, and still a tie because neither number rests on a human endpoint. P-21 boosted hippocampal neurogenesis and restored synaptic markers in rodents, per Baazaoui 2017. Cerebrolysin's plasticity story is inference from review papers, per Al-Kuraishy 2025. Neither side ever registered a plasticity outcome.
Nerve Regeneration	Tie	Dead level at 2.0 each, and neither has an endpoint worth the word. Cerebrolysin's growth-factor-like signaling is described mechanistically, per Plosker and Gauthier 2009, with no trial measuring axonal repair. P-21's neurotrophic activity is consistent in rodents, per Baazaoui 2017, and unproven in people. Stroke recovery scores are rehabilitation, not regrowth.
Healthspan	Tie	Neither, at 1.6 for cerebrolysin and 1.7 for P-21. No healthy-adult trial and no functional-aging endpoint exists on either compound. Cerebrolysin's dementia benefit did not persist past six months, per Gauthier 2015, and the infusion burden makes it impractical as a routine. P-21's aged-rodent work stops at rodents, per Bolognin 2014.
Longevity	Tie	A tie nobody should act on: 1.5 against 1.6. The independent Cochrane stroke review found no benefit on all-cause death, per Ziganshina 2023, which argues against any longevity framing for cerebrolysin. P-21 has no lifespan data, and chronically raising trophic signaling in a healthy person is unstudied, per Bolognin 2014.

Cost Comparison

Intervention	Monthly Cost	Notes
Cerebrolysin	$500 to $900	ESTIMATE, priced 2026-09-07, research-chemical and overseas-pharmacy channel. At about 30 mL per day IV, a 4-week dementia course is 20 infusion days, which is 60 ampoules of 10 mL. Overseas pharmacy resellers price those ampoules at roughly $8 to $14 each.Clinic infusion fees sit on top of that and are not in the figure. This is a channel ESTIMATE, not a measured price, and the studied courses repeat in cycles rather than running once.
P-21	$29 to $48	ESTIMATE, priced 2026-09-08, research-chemical channel. Vendors list 5 mg vials at roughly $48 to $80, about $10 to $16 per mg. At the conservative 100 mcg daily protocol that is 3 mg a month, so about $29 to $48 before reconstitution supplies.Every one of those numbers is an ESTIMATE from vendor listings for material sold for laboratory use. There is no approved product and no human dosing study, so the dose the price is built on is extrapolated from rodents.
The difference	Roughly $470 to $850 a month	P-21 is ESTIMATED at somewhere near a twentieth of a cerebrolysin course, and that spread is the whole reason it gets marketed as the cheap stand-in. Both figures are ESTIMATES, and neither includes the cost of verifying what is in the vial.Price only decides this if the two options are otherwise comparable, and they are not. One has thousands of trial participants and a contested independent verdict. The other has zero human trials, so the cheaper number is buying an untested compound rather than a discount on the same outcome.

When to Switch

The assessment windows are close but the compounds are not. Cerebrolysin's window is 4 weeks, with something noticeable at about 7 days and full effect at 4 weeks, which matches the studied dementia course length. P-21's window is 6 weeks, first noticeable at 4 weeks and full effect at 6, and both of those P-21 figures are ESTIMATES extrapolated from rodent dosing rather than measured in anyone.

Move from P-21 to cerebrolysin when the reason you are taking anything is an actual injury or diagnosed condition: moderate-to-severe brain injury, stroke recovery, dementia. That is where the only human trial base sits, and it is the fork P-21 cannot answer.

Move the other way, from cerebrolysin to P-21, for cost and burden only, and know what you are buying: an ESTIMATED $29 to $48 a month instead of $500 to $900, in exchange for giving up every trial in the comparison. If a cerebrolysin course produced nothing by the end of its 4-week window, the honest next step is stopping, not substituting an untested peptide.

Do not run them together. Both act on the same BDNF-like neurotrophic signaling, so the mechanisms are redundant rather than complementary, and no study on either side has ever combined them. Stacking two growth-factor mimetics multiplies the theoretical proliferation concern that puts active cancer on both contraindication lists, with nothing measured to offset it.

Who Should Pick What?

Adult recovering from moderate-to-severe traumatic brain injury, working with a clinician

Cerebrolysin

This is the one profile with a trial behind it. CAPTAIN II randomized 142 patients at Glasgow Coma Scale 7 to 12 and found a significant benefit at day 90, per Muresanu 2020. The subratings are 4.3 against 2.0. Supervised infusion and verified product are conditions of the recommendation, not details.

Healthy person who wants a sharper brain

Tie

Neither. Cerebrolysin's own contraindication list names healthy adults seeking cognitive enhancement, because no trial shows benefit in a well brain. P-21 has no human trial of any kind. Spending $500 to $900 a month or $29 to $48 a month on this question buys the same amount of evidence, which is none.

Buyer who picked P-21 because an injectable course is unaffordable

Tie

Neither, and this is the fork the page exists for. P-21 is cheap because nobody has run a human trial on it, not because it delivers the same thing for less. Its one independent in-vivo test failed to raise BDNF, per Mottolese 2024. Cheaper access to an unproven compound is not access to the proven one.

Reader who follows preclinical neuroscience and wants to track a molecule

P21 (P021)

P-21 is the more interesting molecule to watch. It is brain-penetrant, orally active in rodents, lowers tau and lifts hippocampal neurogenesis across models, per Kazim 2014 and Khatoon 2015. Tracking the literature costs nothing. Self-administering it is a separate decision with no human data behind it.

Older adult with diagnosed vascular or Alzheimer's dementia

Cerebrolysin

By default and with a clinician, because it is the only one of the two ever randomized in this population. Keep the caveats in view: the cognitive effect faded by six months, per Gauthier 2015, and the independent vascular dementia review rated the evidence very low quality with all studies industry-funded, per Cui 2019.

Anyone with active or prior cancer, epilepsy, or who is pregnant or breastfeeding

Tie

Neither, and this is not a close call. Active or suspected cancer, pregnancy, breastfeeding and seizure history rule out both compounds. Both raise or mimic trophic signaling, and P-21 has zero human safety data to argue with. Cerebrolysin adds porcine protein allergy and severe renal impairment to its own list.

Someone who cannot verify what is in the vial

Tie

Neither. Cerebrolysin is grey-market import of a real injectable biological, where sterility, cold chain and counterfeit risk can exceed the compound's own risk. P-21 is research-chemical material with no reference product to check identity against. Unverifiable input makes both risk profiles unknowable rather than merely uncertain.

Research Highlights

Mechanism Difference
These two are not different approaches to the same problem. They are the same approach at different levels of definition. Cerebrolysin is a porcine brain-derived peptide mixture proposed to cross the blood-brain barrier and act like endogenous neurotrophic factors, hitting BDNF-like, GDNF-like and NGF-like signaling plus calpain and caspase-3.P-21 is a single adamantylated fragment of ciliary neurotrophic factor that crosses the barrier and raises BDNF signaling through CNTFR and TrkB. The shared endpoint is BDNF-like neurotrophic signaling, so the mechanisms are redundant rather than complementary. Cerebrolysin is a mixture, not a defined molecule. P-21 is defined and untested in humans.
Safety Comparison
Neither side has a clean safety file, and they are unclean in different ways. Cerebrolysin has a real one: the independent Cochrane stroke review of seven trials and 1,773 participants found no benefit on death and more non-fatal serious adverse events, per Ziganshina 2023, and dizziness or vertigo is the most commonly reported adverse event in dementia trials.P-21 has no human safety file at all, which is worse than a bad one because nothing can be ruled out. Both score 2.0 on safety risk. Active or suspected cancer, pregnancy, breastfeeding and seizure history rule out both. Cerebrolysin adds porcine protein allergy and severe renal impairment.
Cost Comparison
A cerebrolysin course is ESTIMATED at $500 to $900 a month, priced 2026-09-07: about 30 mL per day IV over 20 infusion days is 60 ampoules of 10 mL, at roughly $8 to $14 each through overseas pharmacy resellers, with clinic infusion fees on top and not included.P-21 is ESTIMATED at $29 to $48 a month, priced 2026-09-08: 5 mg vials at roughly $48 to $80 against a 100 mcg daily protocol, which is 3 mg a month. Both are vendor-channel ESTIMATES, not measured prices, and the P-21 dose the price rests on is extrapolated from rodents.
Editorial Verdict
Cerebrolysin scores 6.3 and P-21 scores 5.0, which is the neutral midpoint and means the data does not support a recommendation in either direction. Cerebrolysin wins every decision-relevant row in the matrix, and it wins them on evidence tier rather than effect size: contested human trials beat unreplicated rodent work.P-21 is marketed as the cheap stand-in for an expensive injectable course. It is cheap because no human trial has ever been run on it. If neither option fits a diagnosed injury or dementia, the honest answer on this page is neither, because no trial on either side has shown anything in a healthy brain.
Evidence Asymmetry
The two evidence bases are not the same size and they do not fail the same way. Cerebrolysin has thousands of trial participants across stroke, brain injury and dementia, with the positive trials maker-funded and two independent Cochrane reviews landing null to negative, per Ziganshina 2023 and Cui 2019.P-21 has zero registered human trials. The single independent in-vivo test rescued cells in culture but failed to raise BDNF or improve neuroanatomy in knockout mice, per Mottolese 2024, and nearly all the positive work comes from the inventor, who co-founded the company licensing it, per Kazim 2017.

Frequently Asked Questions

Is P-21 a cheaper substitute for a cerebrolysin course?: No. It is cheaper, at an ESTIMATED $29 to $48 a month against an ESTIMATED $500 to $900, and it is not a substitute. Cerebrolysin has thousands of human trial participants across stroke, brain injury and dementia. P-21 has zero registered human trials, so the lower price buys an untested compound rather than the same result for less.
Which one scores higher on BioHarmony?: Cerebrolysin, 6.3 and worth trying, against P-21 at 5.0 and neutral. A 5.0 is the middle of the scale and means the evidence does not support a recommendation in either direction. The gap is almost entirely evidence quality: cerebrolysin scores 3.6 on evidence and P-21 scores 1.5.
Does P-21 actually work?: In rodents, repeatedly and across models. It is brain-penetrant, orally active, lowers tau and lifts hippocampal neurogenesis, per Kazim 2014 and Khatoon 2015. In humans, nobody knows, because no trial has been run. The single independent in-vivo test failed to raise BDNF or improve neuroanatomy in knockout mice, per Mottolese 2024, which is the one result not authored by the inventor.
Can I take P-21 orally instead of injecting it?: P021 was orally active in rodents, which is a genuine pharmacologic strength most peptides lack. There is no human oral dosing standard, so any oral protocol you find is extrapolation. The same caution applies to the intranasal route: nose-to-brain delivery in people has never been measured, and the higher acute doses vendors push are folklore rather than protocol.
How long until I know whether either is working?: Cerebrolysin's assessment window is 4 weeks, with a first noticeable change at about 7 days and full effect at 4 weeks, matching the studied dementia course length. P-21's window is 6 weeks, first noticeable at 4 weeks and full effect at 6, and both P-21 figures are ESTIMATES extrapolated from rodent dosing rather than measured in a person.
Can I stack cerebrolysin and P-21?: There is no reason to and no data supporting it. Both converge on BDNF-like neurotrophic signaling, so the mechanisms are redundant rather than complementary. Running two growth-factor mimetics together multiplies the theoretical proliferation concern that already puts active cancer on both contraindication lists, with nothing measured to offset it.
Will either one make a healthy brain sharper?: No trial says so. Cerebrolysin's contraindication list explicitly names healthy adults seeking cognitive enhancement, because no study shows benefit in a well brain, and its human record sits entirely in disease recovery. P-21 has no human data of any kind. The cognition subratings, 4.2 and 2.5, both describe recovery or rodent contexts.
Who should avoid both?: Anyone with active or suspected cancer, anyone pregnant or breastfeeding, and anyone with epilepsy or a seizure history. Cerebrolysin adds known allergy to porcine-derived protein, severe renal impairment and unsupervised IV self-administration without sterile technique. P-21 adds anyone who wants a cognitive intervention with human evidence behind it, since it has none.

Evidence Sources

RCT CASTA: Cerebrolysin in acute ischemic stroke, Stroke (2012) n=1,070, neutral on the primary global outcome at 90 days; 30 mL per day IV for 10 days within 12 hours of onset.
Systematic review Cerebrolysin for acute ischaemic stroke, Cochrane Database of Systematic Reviews (2023) 7 trials, 1,773 participants. No benefit on death (RR 0.96) and more non-fatal serious adverse events. Sponsor supported three studies.
Systematic review Cerebrolysin for vascular dementia, Cochrane Database of Systematic Reviews (2019) 6 trials, 597 participants. Cognition standardized mean difference about 0.36, rated very low quality; all studies industry-funded.
RCT CARS: Cerebrolysin plus standardized rehabilitation after stroke, Stroke (2016) 30 mL per day IV for 21 days plus rehab; arm-recovery effect estimator about 0.71. EVER Pharma staff among the authors.
Meta-analysis Pooled CARS rehabilitation analysis, Neurological Sciences (2017) 442 patients; arm-recovery estimator about 0.62, number-needed-to-treat about 7 for early benefit. Extensive sponsor COI disclosure.
RCT CAPTAIN II in moderate-to-severe brain injury, Neurological Sciences (2020) Single-center, n=142, Glasgow Coma Scale 7 to 12. Small-to-medium multivariate recovery effect significant at day 90; safety comparable to placebo.
Meta-analysis Pooled CAPTAIN brain-injury analysis, Neurological Sciences (2021) n=185; day-30 standardized mean difference about 0.31 and day-90 about 0.34. First author is the sponsor-affiliated biometrician.
Meta-analysis Cerebrolysin in Alzheimer's disease, Dementia and Geriatric Cognitive Disorders (2015) 6 RCTs. Cognition standardized mean difference about 0.40 at 4 weeks, non-significant by 6 months. Maker-affiliated authors.
Narrative review Cerebrolysin in dementia, Drugs and Aging (2009) Narrative review of dementia trials; neurotrophic-like mechanism framing and dizziness or vertigo as the most common adverse event.
Narrative review Cerebrolysin in vascular dementia management, Neuroscience (2025) Independent mechanistic review proposing blood-brain-barrier crossing and neurotrophic-like induction of neurogenesis, plasticity and neuroprotection.
Preclinical P21 founding paper, FEBS Letters (2010) Peripherally administered P21 enhanced learning and memory and induced dentate-gyrus neurogenesis in normal adult mice.
Preclinical Chronic oral P021 in aged rats, Neurobiology of Aging (2014) Reduced age-related learning and memory decline, reversed the neurogenesis deficit and increased BDNF in aged rats.
Preclinical Oral P021 in 3xTg-AD mice, Neurobiology of Disease (2014) Reduced tau hyperphosphorylation and soluble amyloid-beta, raised BDNF, lowered GSK-3beta and rescued cognition in an Alzheimer's model.
Preclinical Peptide 6 after traumatic brain injury, Neurosurgery (2015) The P21 precursor peptide enhanced neurogenesis and memory after traumatic brain injury in a mouse model.
Preclinical P021 blood-brain-barrier permeability and tau, Journal of Alzheimer's Disease (2015) Confirmed barrier permeability; chronic oral P021 reduced brain total tau and lowered elevated CSF tau in aged rats.
Narrative review P021 mechanism review, Molecular Neurodegeneration (2016) LIF inhibition plus BDNF elevation lowering GSK-3beta and tau, with blood-brain-barrier permeability and oral activity.
Preclinical P021 in Down-syndrome model mice, Scientific Reports (2017) Prenatal-to-early-postnatal P021 rescued developmental and Alzheimer's-like memory deficits. Explicit inventor patent conflict disclosed.
Preclinical Dietary P021 and synaptic rescue, Alzheimer's Research and Therapy (2017) Rescued dendritic and synaptic deficits, boosted neurogenesis and reversed cognitive impairment in 3xTg-AD mice.
Preclinical First independent in-vivo test of P021, Journal of Neurodevelopmental Disorders (2024) P021 rescued cells in vitro but failed to raise BDNF or improve neuroanatomy in Cdkl5-knockout mice. Inventor listed as company CSO.

Glossary

Quick reference for the medical and technical terms used in this comparison.

BDNF Brain-Derived Neurotrophic Factor: A growth factor that supports neuron survival and synaptic plasticity. Both compounds aim at BDNF-like signaling, which is why their mechanisms are redundant.
CNTF Ciliary Neurotrophic Factor: A neurotrophic protein. P-21 is an adamantylated fragment epitope-mapped from it, which is where the CNTFR pathway in its mechanism comes from.
TrkB Tropomyosin Receptor Kinase B: The receptor BDNF binds to. P-21's proposed effect runs through raising BDNF signaling at this receptor in rodents.
GCS Glasgow Coma Scale: A 3 to 15 score of consciousness after brain injury. CAPTAIN II enrolled patients at 7 to 12, meaning moderate-to-severe injury.
SMD Standardized Mean Difference: An effect size that lets trials using different scales be pooled. Cerebrolysin's Alzheimer's cognition effect was about 0.40 at four weeks.
COI Conflict of Interest: A financial or authorship stake in the result. It sits on nearly every positive study on both sides of this comparison.
IV Intravenous: Infusion directly into a vein. Cerebrolysin's studied courses are IV, which is why a clinic is usually part of the cost.
IM Intramuscular: Injection into muscle, up to about 5 mL per shot for cerebrolysin. Self-sourcing users often choose it to skip the infusion line.
GSK-3beta Glycogen Synthase Kinase 3 beta: An enzyme that phosphorylates tau. P021 lowered it in Alzheimer's-model mice, which is the proposed route to reduced tau pathology.

Nick Urban Health Optimization Researcher & CHEK Holistic Lifestyle Coach Level 2

Neither report carries a personal rating or review, so this comparison is driven by the live BioHarmony scoring data on both reports and the published evidence they cite

Reviewed Sep 8, 2026 · next review Dec 7, 2026

Find which one fits your biology

Take the BioHarmony Quiz